DSIP vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | DSIP | Tesamorelin |
|---|---|---|
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |